UPDATE 1-Novartis makes history with U.S. launch of 'biosimilar' drug

ZURICH/LONDON, Sept 3 (Reuters) - Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first "biosimilar" copy of a biotechnology drug approved in the United States, following a green light from a U.S. appeals court.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.